Diosgenin Enhances the Sensitivity to Methotrexate Through Oxidative DNA Damage in Saos-2 Osteosarcoma Cancer Cells

Abstract

Background

Previously, diosgenin, a steroidal saponin, has demonstrated therapeutic potential for osteosarcoma. However, the underlying mechanisms still remain unknown.

Objectives

This study was designed to investigate the impact of diosgenin on methotrexate-mediated apoptosis in Saos-2 cells, specifically related to DNA damage.

Methods

To assess the cell vitality of Saos-2 cells, we treated them with methotrexate, diosgenin, and a mixture of both, then performed the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide technique. Western blot was used to evaluate DNA damage by measuring the expression of γ-H2AX protein. The ELISA method was also applied to find the quantity of 8-oxo-2′-deoxyguanosine, and flow cytometry was used to analyze apoptosis.

Results

Combining methotrexate with diosgenin led to a major reduction in cell proliferation rate compared to monotreatments (p<0.05). This combination significantly increased apoptosis, measured by flow cytometry, and increased levels of γ-H2AX protein and 8-oxo-2′-deoxyguanosine.

Conclusion

Diosgenin significantly augmented methotrexate-mediated apoptosis in Saos-2 cells through enhanced DNA damage mechanisms. These findings suggest that diosgenin could serve as a promising adjuvant therapeutic agent to improve the efficacy of current methotrexate-based chemotherapy regimens in osteosarcoma treatment, potentially reducing required drug doses and minimizing associated toxicity while maintaining therapeutic effectiveness.

Keywords

anticancer drugs - apoptosis - cancer - cancer pharmacology

• References

• 1 Czarnecka AM, Synoradzki K, Firlej W. et al. Molecular Biology of Osteosarcoma. Cancers (Basel) 2020; 12 (08) 2130
• 2 Eaton BR, Schwarz R, Vatner R. et al. Osteosarcoma. Pediatr Blood Cancer 2021; 68 Suppl 2 e28352
• 3 Meltzer PS, Helman LJ. New horizons in the treatment of osteosarcoma. N Engl J Med 2021; 385 (22) 2066-2076
• 4 Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol 2021; 18 (10) 609-624
• 5 Bazavar MR, Helali H, Boukani LM. et al. Enhancing Doxorubicin Sensitivity in Osteosarcoma Cancer Cells: Unveiling the Role of Resveratrol-Induced Oxidative DNA Damage. Drug Res 2025; 75 (06) 202-208
• 6 Bazavar M, Fazli J, Valizadeh A. et al. miR-192 enhances sensitivity of methotrexate drug to MG-63 osteosarcoma cancer cells. Pathol Res Pract 2020; 216 (11) 153176
• 7 Yu D, Zhang S, Feng A. et al. Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation. Medicine (Baltimore) 2019; 98 (19) e15582
• 8 Johnson DH, Fehrenbacher L, Novotny WF. et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22 (11) 2184-2191
• 9 Herbst R, Giaccone G, Schiller J. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol 2004; 22: 785-794
• 10 Jesus M, Martins AP, Gallardo E. et al. Diosgenin: recent highlights on pharmacology and analytical methodology. J Anal Methods Chem 2016; 2016: 4156293
• 11 Kim JK, Park SU. An update on the biological and pharmacological activities of diosgenin. EXCLI J 2018; 17: 24
• 12 Holohan C, Van Schaeybroeck S, Longley DB. et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13 (10) 714-726
• 13 Lewis IJ, Nooij MA, Whelan J. et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Nat Cancer Inst 2007; 99 (02) 112-128
• 14 Hernández-Vázquez JMV, López-Muñoz H, Escobar-Sánchez ML. et al. Apoptotic, necrotic, and antiproliferative activity of diosgenin and diosgenin glycosides on cervical cancer cells. Eur J Pharmacol 2020; 871: 172942
• 15 Srinivasan S, Koduru S, Kumar R. et al. Diosgenin targets Akt-mediated prosurvival signaling in human breast cancer cells. Int J Cancer 2009; 125 (04) 961-967
• 16 He Z, Chen H, Li G. et al. Diosgenin inhibits the migration of human breast cancer MDA-MB-231 cells by suppressing Vav2 activity. Phytomedicine 2014; 21 (06) 871-876
• 17 Sethi G, Shanmugam MK, Warrier S. et al. Pro-apoptotic and anti-cancer properties of diosgenin: a comprehensive and critical review. Nutrients 2018; 10 (05) 645
• 18 Ghosh S, More P, Derle A. et al. Diosgenin functionalized iron oxide nanoparticles as novel nanomaterial against breast cancer. J Nanosci Nanotechnol 2015; 15 (12) 9464-9472